A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL1RAP antibody) alone or in combination with current therapies of azacitidine (HMA) and venetoclax (Bcl-2 inhibitor), is an effective treatment strategy for high-risk MDS and AML, and with a clinical trial we will establish the safety and the early efficacy of this approach.

Start Date05 Mar 2025

Sponsor / Collaborator-

NCT05181462

/ Active, not recruitingPhase 1/2

A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer. "TRIFOUR Study"

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2 protein, so unlike other types of BC, TNBC, which is an aggressive form of BC, does not have specific effective therapies available being the least common form of BC and the most difficult to treat.
Advanced or metastatic TNBC is treated with combinations of platinum-based chemotherapy with taxanes or gemcitabine with a 5-year survival rate of 12%. Recent studies have shown that TNBC expresses Interleukin 1 Receptor Accessory Protein (IL1RAP) at higher levels than other forms of BC.
Nadunolimab is a fully humanized monoclonal antibody that blocks the signals that occur within the cell produced by IL1RAP protein, thereby impairing the cancer cells' ability to secrete tumor stimulating substances, in turn reducing the tumor, inflammation and tumor progression. On the other hand, it is an antibody designed to activate the immune system to fight cancer cells.
This clinical trial is divided into two phases, phase Ib in which it is expected to include up to 15 patients and phase II in which it is expected to include 102 patients. The main purpose of phase Ib is to ensure that the combination of nadunolimab plus chemotherapy (gemcitabine plus carboplatin) is safe and determine the highest dose of nadunolimab that can be given safely without causing serious side effects. If the pre-specified objectives in this part are achieved, the trial will be expanded to a randomized phase II, to evaluate the efficacy of the combination of nadunolimab plus gemcitabine plus carboplatin, compared to a control group that will receive gemcitabine plus carboplatin only.

Start Date11 Jan 2022

Sponsor / Collaborator

Cantargia AB

[+1]

EUCTR2021-001695-42-ES

/ Unknown statusPhase 1/2

A Phase 1/2 study of CAN04, a fully humanised monoclonal antibody against IL1RAP, in combination with different chemotherapy regimens in subjects with advanced solid tumours

Start Date22 Sep 2021

Sponsor / Collaborator

Cantargia AB

100 Clinical Results associated with Nadunolimab

100 Translational Medicine associated with Nadunolimab

100 Patents (Medical) associated with Nadunolimab

Literatures (Medical) associated with Nadunolimab

01 Sep 2025·LUNG CANCER

Letter to the editor: Critical analysis of the CANFOUR trial on nadunolimab in advanced NSCLC

Letter

Author: Yang, Zongyu ; Liao, Songjie

01 Aug 2025·LUNG CANCER

Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet

Article

Author: Zvirbule, Zanete ; Magnusson, Susanne ; Thorsson, Lars ; Paz-Ares, Luis G ; Garcia-Ribas, Ignacio ; Paulus, Astrid ; Zemaitis, Marius ; Millrud, Camilla Rydberg ; Tersago, Dominique ; Sanfridson, Annika ; Losic, Nedjad ; Cicenas, Saulius

INTRODUCTION:

Interleukin-1 receptor accessory protein (IL1RAP), expressed in several tumors, is essential for IL-1α and IL-1β signaling which leads to tumor progression and treatment resistance. Nadunolimab, a fully humanized antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody, targets IL1RAP and blocks IL-1α/IL-1β signaling. Efficacy and safety of nadunolimab plus platinum-based doublet chemotherapies were assessed in patients with non-small cell lung cancer (NSCLC) (NCT03267316).

METHODS:

Patients with advanced NSCLC received nadunolimab plus platinum-based doublet chemotherapies in first-line or second-line post-pembrolizumab. Study objectives included the anti-tumor response, progression-free survival (PFS), overall survival (OS), levels of biomarkers in serum, and immunohistochemistry of baseline and on-treatment tumor biopsies.

RESULTS:

43 patients were enrolled, median age 64 years, 38 % female, and 43 % were treated in second-line post-pembrolizumab. Median PFS was 7.2 months (95 % CI 5.6-9.2), median OS was 13.7 months (95 % CI 11.1-18.3), and 1-year survival was 54 %. The greatest benefits were observed in 11 patients with non-squamous histology treated in second-line post-pembrolizumab: median OS 26.7 months, ORR 91 % including two complete responders (with distinct biomarker profiles), and 1-year survival 82 %. Biomarker analyses showed that patients in second-line post-pembrolizumab had an enhanced level of tumor-infiltrating immune cells compared to treatment naïve patients. Rates of Grade 3+ neutropenia, anemia, and thrombocytopenia were higher than previous reports of platinum-based doublet chemotherapies alone.

CONCLUSIONS:

Nadunolimab plus platinum-based doublet chemotherapies showed promising efficacy in advanced NSCLC, with the greatest benefit in patients with non-squamous histology treated in second line after relapsing on pembrolizumab treatment.

01 Jun 2025·INVESTIGATIONAL NEW DRUGS

Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors

Article

Author: Jimeno, Antonio ; Cohen, Roger B ; Millrud, Camilla Rydberg ; Sanfridson, Annika ; Hreno, Jennifer ; Garcia-Ribas, Ignacio ; Wallén-Öhman, Marie ; Sun, Lova

Summary:

Interleukin (IL)-1 signaling has an essential role in tumor progression and immunosuppression and is linked to acquired resistance to anti-PD-1/PD-L1 treatment. Nadunolimab is an IL1RAP (IL-1 receptor accessory protein)-targeting antibody that blocks IL-1α/IL-1β signaling and has enhanced antibody-dependent cellular cytotoxicity. We investigated the safety and preliminary efficacy of nadunolimab with pembrolizumab in patients with metastatic solid tumors who had progressed on previous checkpoint inhibitor treatment, suggesting acquired checkpoint inhibitor resistance (NCT04452214). This phase 1b trial enrolled patients with metastatic disease who had exhausted or declined standard-of-care alternatives. Patients received nadunolimab (5 mg/kg) and standard-dose pembrolizumab. The primary objective was to assess safety. Secondary objectives were anti-tumor response as per iRECIST, pharmacokinetics, and changes in immune mediators. Fifteen patients with stage IV cancer (head and neck squamous cell carcinoma, non-small cell lung cancer, melanoma) entered the trial. Grade ≥ 3 adverse events were reported for 7 patients (47%). There was one dose-limiting toxicity of febrile neutropenia. The most frequent grade ≥ 3 adverse event was dysphagia (two patients). Seven patients (47%) had reductions in target lesion size. Median iPFS was 3.4 months (95% CI 1.4–8.6). Median OS was 19.7 months (95% CI 4.3–28.7) with 67% 1-year survival. Survival was significantly longer in patients with higher baseline tumor infiltration of CD163 + macrophages and natural killer cells and in patients with reduced on-treatment circulating IL-6 levels or neutrophil-to-lymphocyte ratio. Nadunolimab with pembrolizumab had an acceptable safety profile, and prolonged disease control was observed in a subset of patients. The results support further development of nadunolimab in combination with checkpoint inhibitors.

News (Medical) associated with Nadunolimab

07 Nov 2025

·www.prnewswire.com

Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025

HONG KONG, Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) published the preclinical research data for its novel antagonistic monoclonal antibody targeting IL-1RAP, AK135, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. The results demonstrated that AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36 at their source, thereby halting the transmission of inflammatory signals. In preclinical models, AK135 provided significant pain relief in neuropathy, exhibiting dose-dependent efficacy, while also showing good tolerability and safety profiles. In vitro Results: ELISA, Fortebio molecular interaction technology, and flow cytometry (FACS) results demonstrated that AK135 has high affinity for IL-1RAP, with binding activity comparable to or superior to that of the control antibody CAN04. Reporter gene assays further confirmed that AK135 effectively inhibits the activation of IL-1, IL-33, and IL-36 signaling pathways, showing excellent half-maximal inhibitory concentration (IC50) values in each of the pathways. In tumor cell models, AK135 significantly reduced the secretion of pro-inflammatory cytokines (such as IL-6 and IL-8) induced by IL-1, IL-33, and IL-36. In vivo Results: The in vitro experiments confirmed the high affinity and potent neutralizing activity of AK135. To further evaluate its in vivo efficacy, the research team established a Chemotherapy-induced peripheral neuropathy (CIPN) mouse model and assessed the pharmacological effects of AK135 through intermittent low-dose paclitaxel administration. Following AK135 treatment, the paw withdrawal threshold (PWT) in the CIPN model was significantly increased, indicating that AK135 effectively alleviated mechanical allodynia, with a dose-dependent efficacy. Throughout the treatment period, mice in all dose groups maintained stable body weight, with no significant signs of toxicity, demonstrating good tolerance. CIPN is a prevalent and dose-limiting side effect of chemotherapy, affecting 50-90% of treated patients, of which 30-40% progressing to chronic neuropathic pain. Despite its clinical significance, effective treatment options remain limited, and the underlying mechanisms are not fully understood. Emerging evidence suggests that pro-inflammatory cytokines released by the damaged neurons play a key role in CIPN pathogenesis. IL-1 receptor accessory protein (IL-1RAP/IL-1RAcP) is a critical mediator of inflammatory signaling, amplifying responses through the interleukin-1 (IL-1), interleukin-33 (IL-33), and interleukin-36 (IL-36) pathways. Akeso developed AK135, a novel antagonistic monoclonal antibody targeting IL-1RAP, to alleviate the peripheral neuralgia by inhibiting these proinflammatory signaling pathways. About AK135 (IL-1RAP Targeting Antibody) AK135 is a novel antagonistic antibody targeting IL-1RAP, internally developed by Akeso, aimed at treating chemotherapy-induced peripheral neuropathy (CIPN). By precisely blocking IL-1RAP, this product simultaneously inhibits the three core inflammatory signaling pathways—IL-1, IL-33, and IL-36, providing relief from neuroinflammatory responses at their source. Preclinical studies have shown that AK135 significantly alleviates neuropathic pain in a dose-dependent manner, while also demonstrating good tolerance. Currently, AK135 is in Phase I clinical trials for the treatment of CIPN. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. SOURCE Akeso, Inc. 21% more press release views with Request a Demo

Phase 1ImmunotherapyAACRClinical Result

18 Jul 2025

·pipelinereview.com

Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)

July 17, 2025 I TRIFOUR is an exploratory open label randomized Phase 1b/2 clinical study conducted by the Spanish Breast Cancer Group (GEICAM). The objective is to evaluate early signals of efficacy of Cantargia’s IL1RAP antibody nadunolimab in TNBC, with unconfirmed ORR as primary endpoint. The ORR was 40% in the Ph2 study in the nadunolimab plus GC treated patients. As reference, the ORR in the GC group was 43%. Subgroup analyses of the data are ongoing. The tolerability of the combination was acceptable and in line with previous trials combining nadunolimab and chemotherapy. Most common side effects in this trial were neutropenia and asthenia with no notable differences between the two study arms. “TNBC is a heterogeneous and difficult to treat disease, with a high unmet medical need. We welcome the efforts to explore new treatments and appreciate the learnings we are making from the TRIFOUR study. We now await the outcome of further analyses from the study, including overall survival,” said Dr. Eva Carrasco, CEO of GEICAM. “We are pleased to have the opportunity to collaborate with GEICAM and explore nadunolimab in the TNBC indication. While the preliminary ORR results of the Phase 2 part of the TRIFOUR trial do not match those obtained in the Phase 1b part of the trial, the study continues and we will now await the mature survival data.” said Damian Marron, interim CEO of Cantargia. “Following the signing of our CAN10 agreement earlier this week, we will be undertaking a detailed portfolio discussion to define our plans for the further development of nadunolimab”. The TRIFOUR Ph1b/2 study first enrolled 15 patients in a preliminary phase 1b dose-ranging part, which showed an acceptable safety profile with promising efficacy including 73% unconfirmed ORR (60% confirmed) in first-line (1L) or second-line (2L) patients with metastatic TNBC. In the Phase 2 part of the trial, patients were randomized to two study groups with nadunolimab + GC treatment in the experimental group (n=51) and GC alone in the reference group (n=48). Nadunolimab (2.5 mg/kg) and GC were given twice per cycle in 3- or 4-week cycles. The objective of the study was to identify early signals of efficacy, with an internal GC group for reference. RECIST 1.1 criteria were used to evaluate the preliminary ORR which was based on a minimum of 2 CT scans (approx. 3 months treatment) from the 97 TNBC patients included in the efficacy analyses. Among these, 20 patients (40%) showed unconfirmed complete response (CR) or partial response (PR) in the nadunolimab + GC arm vs. 20 patients (43%) in the chemotherapy arm. This data in 1L and 2L patients is higher than the historical response rate of approximately 30% reported for GC alone in 1L, 2L and third-line patients [1], and similar to 1L TNBC patients treated with chemotherapy alone [2]. Nadunolimab has been tested in over 300 patients with metastatic cancer. Previous data in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) indications have shown promising results for nadunolimab in combination with chemotherapy in these indications [3,4], and nadunolimab is granted Fast Track designation from the U.S. Food and Drug Administration (FDA) in PDAC patients with high expression levels of IL1RAP. Nadunolimab is currently being tested inpatients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in an investigator-initiated clinical study at The University of Texas MD Anderson Cancer Center. More details of the TRIFOUR study will be communicated at an upcoming scientific conference. References [1] O’Shaughnessy, J Clin Oncol 2014, 32:3840-3847 [2] Cortes N Engl J Med 2022, 387: 217-226 [3] van Cutsem et al, Clin Cancer Res 2024, 30: 5293-5303 [4] Paulus et al, Lung Cancer 2025, https://doi-org.libproxy1.nus.edu.sg/10.1016/j.lungcan.2025.108664 About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com . About nadunolimab (CAN04) The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316 , evaluates nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase 1b/2 trial TRIFOUR, NCT05181462 , also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine. About GEICAM GEICAM is the leader group in breast cancer research in Spain with a recognized worldwide prestige. It is formed by more than 900 experts, who work in 220 institutions throughout Spain. Since its establishment in 1995 until now GEICAM has performed more than a hundred of studies in which almost 68,000 women and men have participated. It has a large multidisciplinary team specialized in the management of clinical trials and other studies, which collaborates with clinical researchers in the design and implementation of clinical trials, as well as in their execution and dissemination in forums and high-impact scientific journals. For more information, you can visit the official website http://www.geicam.org or follow us on Twitter @GEICAM, @GEICAMujer, and on Facebook.com/GEICAM. SOURCE: Cantargia

Clinical ResultFast TrackPhase 2Phase 1

18 Jul 2025

·endpoints.news

Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes

Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics: Bristol Myers Squibb suffers late-stage miss in anemia: Patients with myelofibrosis-associated anemia taking Reblozyl were no more able than those on placebo to go three months without a red blood cell transfusion in a Phase 3 trial. There was a numerical and clinically meaningful improvement in transfusion independence favoring the product, which is intended to boost levels of a patient’s native red blood cells, BMS said . However, this was not significant at p=0.0674. BMS said it was “encouraged” by the results and would discuss filing plans with regulators. — Elizabeth Cairns Sanofi closes $9.1B acquisition of Blueprint Medicines: It’s the second largest biopharma deal of the year after Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular Therapies in January. — Jaimy Lee DiaMedica Therapeutics’ Phase 2 success in pre-eclampsia: The biotech’s DM199 achieved prespecified safety and efficacy endpoints in the dose-escalation part of the mid-stage study, including dose-dependent reductions in systolic and diastolic blood pressure. There were no cases of placental transfer and no serious side effects in any cohort, the company said Thursday. — Ayisha Sharma Cantargia’s IL1RAP antibody flops: An open-label Phase 1b/2 study found a 40% overall response rate (ORR) among triple-negative breast cancer patients taking the Swedish biotech’s nadunolimab plus carboplatin and gemcitabine. It also produced a 43% ORR in a control group taking the latter two drugs. Addition of the drug did not alter the chemo’s safety profile, according to Cantargia. — Elizabeth Cairns Quetzal Therapeutics launches with $50M: The company has two assets: QTX-2101, a mid-stage oral arsenic trioxide therapy for acute promyelocytic leukemia, and QTX-2102, a preclinical antifungal and antiparasitic therapy. It’s run by Usman Ahmed, the former CEO of Nexus Pharmaceuticals. — Jaimy Lee

Clinical ResultPhase 3AcquisitionPhase 2

100 Deals associated with Nadunolimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 2	United States	Cantargia AB	20 Feb 2024
Advanced Triple-Negative Breast Carcinoma	Phase 2	Spain	Cantargia AB	11 Jan 2022
Advanced Malignant Solid Neoplasm	Phase 2	France	Cantargia AB	22 Sep 2021
Advanced Malignant Solid Neoplasm	Phase 2	Spain	Cantargia AB	22 Sep 2021
Gallbladder Neoplasms	Phase 2	France	Cantargia AB	22 Sep 2021
Gallbladder Neoplasms	Phase 2	Spain	Cantargia AB	22 Sep 2021
Intrahepatic Cholangiocarcinoma	Phase 2	France	Cantargia AB	22 Sep 2021
Intrahepatic Cholangiocarcinoma	Phase 2	Spain	Cantargia AB	22 Sep 2021
Non-Small Cell Lung Cancer	Phase 2	France	Cantargia AB	22 Sep 2021
Colorectal Cancer	Phase 2	Austria	Cantargia AB	19 Sep 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05181462 (TRIFOUR, PipelineReview) Manual	Phase 1/2	Advanced Triple-Negative Breast Carcinoma HER2 Negative \| PR Negative \| ER Negative	99	nadunolimab+Gemcitabine+Carboplatin	tztvyxuufg(ekebktkkbr) = zvlrqybrzh bsthqkpoqn (ctfgzrdubn )	Negative	18 Jul 2025
				Gemcitabine+Carboplatin	tztvyxuufg(ekebktkkbr) = yyulamnmzl bsthqkpoqn (ctfgzrdubn )
NCT05181462 (TRIFOUR, SABCS2024 \| Company_Website) Manual	Phase 1/2	Advanced Triple-Negative Breast Carcinoma	15	Nadunolimab gemcitabine+ carboplatin	xjzbpdghxv(ztserbrkkg) = zdiyzjzokg vtrtoanfqt (vbfwzydfjw, 32 - 84) View more	Positive	10 Dec 2024
NCT05116891 (CESTAFOUR, Company_Website) Manual	Phase 1/2	Neoplasms \| Non-Small Cell Lung Cancer \| Biliary Tract Neoplasms	-	Nadunolimab in combination with gemcitabine/cisplatin (NSCLC + first arm)	nmjkqbsnqb(bwosgeaewb) = zpiorhiqgn qttfqajrsg (akippxfozy ) View more	Positive	28 Oct 2024
				Nadunolimab in combination with gemcitabine/cisplatin (biliary tract cancer + first arm)	nmjkqbsnqb(bwosgeaewb) = shqlaeikfv qttfqajrsg (akippxfozy ) View more
NCT05116891 (CANFOUR, ESMO2024) Manual	Phase 1/2	Non-Small Cell Lung Cancer First line \| Second line	40	Nadunolimab cisplatingemcitabine	ckpcyakfjt(qqifcwlyxx) = dyftmyfbuy bsbmmrnrvp (yeeygkibvl ) View more	Positive	14 Sep 2024
				Nadunolimab cisplatingemcitabine	ckpcyakfjt(qqifcwlyxx) = wywnqinbph bsbmmrnrvp (yeeygkibvl ) View more
NCT04452214 (ESMO2024) Manual	Phase 1	Solid tumor \| Squamous Cell Carcinoma of Head and Neck \| Melanoma ... Second line View more	15	Nadunolimab 5 mg/kg + Pembrolizumab	ykxtzpxoax(nyqcxdrxmt) = 1(G3 febrile neutropenia) fvgsgihciv (urjlheykry ) View more	Positive	14 Sep 2024
NCT03267316 (CANFOUR, ASCO2024)	Phase 1/2	Pancreatic Cancer	73	Nadunolimab 1 mg/kg	ahwecempby(bdfuzueech) = nzrghkuhnz pmacirkbje (bdvzxqcfhi ) View more	Positive	24 May 2024
				Nadunolimab 2.5 mg/kg	ahwecempby(bdfuzueech) = bxrerbmhog pmacirkbje (bdvzxqcfhi ) View more
NCT05181462 (TRIFOUR, ESMO 12023 \| ESMO 22023) Manual	Phase 1/2	Triple Negative Breast Cancer HER2 Negative \| ER Negative \| PR Negative	13	nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 1 mg/kg)	ixlkzqnzxv(eppkiuuquf) = xdtrkjxfqp noltqhnjja (gijwcprihq )	Positive	21 Oct 2023
				nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 2.5 mg/kg)	ixlkzqnzxv(eppkiuuquf) = dkzuoppade noltqhnjja (gijwcprihq )
NCT03267316 (ASCO2023)	Phase 1/2	Non-Small Cell Lung Cancer	30	Nadunolimab 1 mg/kg + cisplatin/gemcitabine	elsjrbimmq(kwldwhptbu) = pinizidytn czgwvrjzzs (nsgukzejxn, 3.7 - 7.5) View more	Positive	31 May 2023
				Nadunolimab 2.5 mg/kg + cisplatin/gemcitabine	xtgowdvuym(cvtehzfkgi) = tuufnmnhjo kyjmbiublp (deadfrhzrd )
NCT03267316 \| NCT05116891 (CANFOUR, AACR2023)	Phase 1/2	Pancreatic Ductal Adenocarcinoma	73	Nadunolimab	gsfantuhzz(sjsipejnng) = xmpgwhyvis tzimchsnqs (qcytdwzzky, 10.0 - 19.1) View more	-	04 Apr 2023
NCT03267316 (CANFOUR, ASCO2022) Manual	Phase 1/2	Pancreatic adenocarcinoma	76	gemcitabine+nab-paclitaxel+nadunolimab	ihmzdifakl(kthkyetiiq) = Infusion-related reactions were reported in 29% (grade 3 in 3%). Peripheral sensory neuropathy was rare (only two grade 2 events). akcauyymaa (jbkohdsnld ) View more	Positive	02 Jun 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nadunolimab

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation